| Predicate |
Object |
| assignee |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_ce4af9c5b46a659226741b345aaf44db
http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_dbbe4ed80d4c19b9f1b8fa19a35aba39
http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_fcb8688636431bbf06cf69df9289e2fa
http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_59c6a921f33fe0adc58c2b6177184515
http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_a92445b03d3abcd046386534d7f3b88f
http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_967fbe1d5d710204341f248e1ab5152b
http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_471357c16fd4ce68bc752c8a4eb208cd |
| classificationCPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K35-14
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K35-30
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K38-185
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K38-1866
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P7-06
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P9-10
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P25-28 |
| classificationIPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P25-28
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P7-06
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K38-18
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K35-14 |
| filingDate |
2009-11-13-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| inventor |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_1608fbeb633316c72380208adfb474b3
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_772822a6a8ef0544f0d4455151f76d28
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_5d3fb926b53c742ad59e910b7455bf9e |
| publicationDate |
2010-05-20-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationNumber |
WO-2010056988-A2 |
| titleOfInvention |
Methods of treating stroke using stem cell-like menstrual blood cells |
| abstract |
A cell type that is a complete match of the transplant recipient appears as an optimal scenario to open treatment options to a large patient population with minimal complications. The use of autologous bone marrow or umbilical cord blood has been proposed as a good source of stem cells for cell therapy. Menstrual blood is found to be another important source of stem cells. Assays of cultured menstrual blood reveal that they express embryonic like-stern cell phenotypic markers and neuronal phenotypic markers under appropriate conditioned media. Oxygen glucose deprivation stroke models show that OGD-exposed primary rat neurons, co- cultured with menstrual blood-derived stem cells or exposed to the media from cultured menstrual blood, exhibited significantly reduced cell death. Transplantation of menstrual blood-derived stem cells, either intracerebrally or intravenously, after experimentally induced ischemic stroke in adult rats also significantly reduced behavioral and histological impairments compared to vehicle-infused rats. |
| priorityDate |
2008-11-13-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| type |
http://data.epo.org/linked-data/def/patent/Publication |